Long-term treatment costs and cost-effectiveness of restoration repair versus replacement

被引:7
|
作者
Kanzow, Philipp [1 ]
Krois, Joachim [2 ]
Wiegand, Annette [1 ]
Schwendicke, Falk [2 ]
机构
[1] Univ Med Ctr Gottingen, Dept Prevent Dent Periodontol & Cariol, Robert Koch Str 40, D-37075 Gottingen, Germany
[2] Charite Univ Med Berlin, Dept Oral Diagnost Digital Hlth & Hlth Serv Res, Berlin, Germany
关键词
Composite materials; Cost-effectiveness; Minimally invasive dentistry; Restoration repair; Restorative dentistry; Treatment costs; POSTERIOR COMPOSITE RESTORATIONS; LONGEVITY; MOLARS; CARE;
D O I
10.1016/j.dental.2021.02.008
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Objectives. When managing partially defective restorations, dentists can choose between repair and replacement. We aimed to assess the long-term treatment costs of repairs and replacements. Methods. Partially defective anterior and posterior composite restorations in permanent teeth had been repaired or replaced in a German university hospital and were retrospectively followed until censoring or one of the following events: (1) Extraction, (2) Major complications including placement of indirect restorations, endodontic treatments and extractions, or (3) Any complications including major complications and further direct restorations. Costs were estimated from a German mixed public-private-payer perspective. Cost-effectiveness differences were described using median-based incremental-cost-effectiveness ratios (ICERMEDIAN). Statistical analysis was performed using generalized linear mixed modeling (GLM), Chi(2)-test, and Wilcoxon rank-sum test (p < 0.05). Results. A total of 616 repairs in 468 patients (follow-up: 4.9 +/- 4.1 years) and 264 replacements in 218 patients (follow-up: 4.8 +/- 4.3) were included. While replacements were associated with higher initial treatment costs, median annualized treatment costs did not significantly differ between repair (47.58 Euro [IQR: 24.41-107.04]) and replacement (50.64 Euro [IQR: 26.30-118.78]; p > 0.05), but were higher for molars (75.53 Euro [IQR: 24.41-92.18]) than incisors (45.03 Euro [IQR: 28.19-168.50]; p = 0.011). The difference in the % of extractions, major and any complications were minimal between both groups. The mean ICERMEDIAN of replacement vs. repair was -146.8 Euro/% when extractions were considered as outcomes. Regarding major and any complications, mean ICERMEDIAN amounted to 67.6 Euro/% and 23.9Euro/%, respectively. Significance. Repairs and replacements of partially defective restorations showed similar long-term costs and cost-effectiveness. (C) 2021 The Academy of Dental Materials. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:E375 / E381
页数:7
相关论文
共 50 条
  • [31] Long-term Cost-effectiveness of Statin Treatment for Primary Prevention of Cardiovascular Disease in the Elderly
    Lin, Liang
    Teng, Monica
    Zhao, Ying Jiao
    Khoo, Ai Leng
    Seet, Raymond Chee Seong
    Yong, Quek Wei
    Yeo, Tiong Cheng
    Lim, Boon Peng
    CARDIOVASCULAR DRUGS AND THERAPY, 2015, 29 (02) : 187 - 197
  • [32] A Review of Methods Used in Long-Term Cost-Effectiveness Models of Diabetes Mellitus Treatment
    Tarride, Jean-Eric
    Hopkins, Robert
    Blackhouse, Gord
    Bowen, James M.
    Bischof, Matthias
    Von Keyserlingk, Camilla
    O'Reilly, Daria
    Xie, Feng
    Goeree, Ron
    PHARMACOECONOMICS, 2010, 28 (04) : 255 - 277
  • [33] Long-term cost-effectiveness analysis of sacral neuromodulation in the treatment of severe faecal incontinence
    Valencia, Mario de Miguel J.
    Hita, Juan Cabases M.
    Iriso, Eduardo Sanchez
    Martinez, Fabiola Oteiza
    Ibanez, Inaki Alberdi
    Lopez, Alfonso Alvarez
    Hurtado, Hector Ortiz
    Velasco, Mario J. de Miguel J.
    COLORECTAL DISEASE, 2023, 25 (09) : 1821 - 1831
  • [34] Long-Term Cost-Effectiveness of Pioglitazone versus Placebo in Addition to Existing Diabetes Treatment: A US Analysis Based on PROactive
    Valentine, William J.
    Tucker, Daniel
    Palmer, Andrew J.
    Minshall, Michael E.
    Foos, Volker
    Silberman, Cheryl
    VALUE IN HEALTH, 2009, 12 (01) : 1 - 9
  • [35] A Review of Methods Used in Long-Term Cost-Effectiveness Models of Diabetes Mellitus Treatment
    Jean-Eric Tarride
    Robert Hopkins
    Gord Blackhouse
    James M. Bowen
    Matthias Bischof
    Camilla Von Keyserlingk
    Daria O’Reilly
    Feng Xie
    Ron Goeree
    PharmacoEconomics, 2010, 28 : 255 - 277
  • [36] The long-term cost-effectiveness of once-weekly semaglutide versus sitagliptin for the treatment of type 2 diabetes in China
    Shuyan Gu
    Jinghong Gu
    Xiaoyong Wang
    Xiaoling Wang
    Lu Li
    Hai Gu
    Biao Xu
    Health Economics Review, 14
  • [37] The long-term cost-effectiveness of once-weekly semaglutide versus sitagliptin for the treatment of type 2 diabetes in China
    Gu, Shuyan
    Gu, Jinghong
    Wang, Xiaoyong
    Wang, Xiaoling
    Li, Lu
    Gu, Hai
    Xu, Biao
    HEALTH ECONOMICS REVIEW, 2024, 14 (01)
  • [38] Long-term Cost-effectiveness of Statin Treatment for Primary Prevention of Cardiovascular Disease in the Elderly
    Liang Lin
    Monica Teng
    Ying Jiao Zhao
    Ai Leng Khoo
    Raymond Chee Seong Seet
    Quek Wei Yong
    Tiong Cheng Yeo
    Boon Peng Lim
    Cardiovascular Drugs and Therapy, 2015, 29 : 187 - 197
  • [39] A COST-EFFECTIVENESS ANALYSIS OF ALTERNATIVE APPROACHES FOR LONG-TERM TREATMENT OF PROXIMAL VENOUS THROMBOSIS
    HULL, R
    RASKOB, G
    HIRSH, J
    THROMBOSIS AND HAEMOSTASIS, 1983, 50 (01) : 66 - 66
  • [40] Long-term Clinical Outcomes and Cost-Effectiveness of Obeticholic Acid for Treatment of Nonalcoholic Steatohepatitis
    Chhatwal, Jagpreet
    Samur, Sumeyye
    Klebanoff, Matthew
    Corey, Kathleen E.
    Banken, Reiner
    Chapman, Richard H.
    Ollendorf, Daniel A.
    Hur, Chin
    HEPATOLOGY, 2016, 64 : 53A - 54A